A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease

Gut

Volumn 59, Issue 6, 2010, Pages 760-766

  Dotan, Iris ^a   Rachmilewitz, Daniel ^b   Schreiber, Stefan ^c   Eliakim, Rami ^d   Van Der Woude, C Janneke ^e   Kornbluth, Asher ^f   Buchman, Alan L ^g   Bar Meir, Shimon ^h   Bokemeyer, Bernd ⁱ   Goldin, Eran ^j   Maaser, Christian ^k   Mahadevan, Uma ^l   Seidler, Ursula ^m   Hoffman, Jörg C ⁿ   Homoky, Douglas ^o   Plasse, Terry ^p   Powers, Barbara ^p   Rutgeerts, Paul ^q   Hommes, Daniel ^r  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c UNIVERSITY OF KIEL   (Germany)

^d Rambam Health Care Campus ^*  (Israel)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ KLINIKUM MINDEN   (Germany)

^j HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^k UNIVERSITY OF MÜNSTER   (Germany)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m HANNOVER MEDICAL SCHOOL   (Germany)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o Gastroenterology Associates   (United States)

^p Cytokine PharmaSciences Inc   (United States)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^r LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; PLACEBO; SEMAPIMOD;

ADULT; ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CROHN DISEASE ENDOSCOPIC INFLAMMATION SCORE; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INFESTATION; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPEN STUDY; OPPORTUNISTIC INFECTION; OPTIMAL DRUG DOSE; ORAL PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SHORT COURSE THERAPY; SIDE EFFECT; SKIN DISEASE; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; C-REACTIVE PROTEIN; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; HYDRAZONES; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953703822     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.179994     Document Type: Article

References (21)

1. Van Deventer SJH. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
2. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor-alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
3. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
4. Van Dullemen HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1399-405.
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
7. Bickston G, Lichtenstein K, Arseneau R, et al. Increased malignancies with biologics. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999;117:1433-7 S.
8. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007;13:1299-307.
9. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30
10. Hommes DW, Peppelenbosch MP, Van Deventer SJ. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 2003;52:144-51.
11. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-12.
12. Van den Blink B, Hove TT, Van den Brink GR, et al. From extracellular to intracellular targets inhibiting MAP kinases in treatment of Crohn's disease. Acad Sci 2002;973:349-58.
13. Mihara K, Almansa C, Smeets RL, et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha. Br J Pharmacol 2008;154:153-64.
14. Hollenbach E, Vieth M, Roessner A, et al. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem 2005;280:14981-8.
15. Bianchi M, Bloom O, Raabe T, et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med 1996;83:927-36.
16. Bjork L, Tracey KJ, Ulrich P, et al. Targeted suppression of cytokine production in monocytes but not in T-lymphocytes by a tetravalent guanylhydrazone (CNI-1493). J Infect Dis 1997;176:1303-12. (Pubitemid 27460997)
17. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7-14. (Pubitemid 34049188)
18. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's disease study. Gastroenterology 1976;70:439-44.
19. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96:804-10. (Pubitemid 19057603)
20. Cohen PS, Nakshatri H, Dennis J, et al. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc Natl Acad Sci USA 1996;93:3967-71.
21. Löwenberg M, Verhaar A, van den Blink B, et al. Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol 2005;175:2293-300. (Pubitemid 41113837)